Re-treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies offers a promising approach to extend the continuum of care of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) with no mutations of resistance in their circulating tumor DNA (ctDNA) at the time of treatment re-exposure.
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO☆
Annals of Oncology | | P. Ciracì, M.M. Germani, F. Pietrantonio, P. Manca, S. Lonardi, A. Busico, F. Bergamo, V. Burgio, F. Mannavola, S. Di Donato, E. Fenocchio, F. Palermo, I. Capone, M.C. De Grandis, N. Pella, M. Scartozzi, L. Antonuzzo, A. Passardi, M. Claravezza, L. Salvatore, S. Tamberi, G. Randon, E. Conca, V. Conca, C. Antoniotti, R. Moretto, G. Masi, L. Boni, D. Rossini, C. Cremolini, GONO Foundation Investigators
Topics: lung-cancer, colorectal-cancer, targeted-therapy, chemotherapy, new-technology, research